A leading partner in a multinational, industry-sponsored trial of the Argus II retinal implant in blind eyes, Moorfields contributed seven patients, making it the highest recruiting centre worldwide

Patients taking part had progressively lost vision in both eyes until they were completely blind due to inherited retinal disease. Post-surgery, the patients could read large letters and perform standardised visual tasks, demonstrating the feasibility of this approach to blindness treatment. The study was presented at an FDA Open Hearing Day in October 2013, following which the device was licensed.